Sanofi and Earendil Labs enter into deal for bispecific autoimmune therapies worth a total of $2.56 billion. This is the second such agreement in the recent history of the French pharmaceutical giant. The deal will strengthen Sanofi's immunology development pipeline. Earendil Labs will receive an upfront payment of $125 million. The collaboration focuses on advanced therapies against autoimmune diseases. This move follows Sanofi's previous investments in similar areas.[2]